Literature DB >> 32176221

Prophylaxis of breast cancer chemotherapy for bone marrow toxicity: more individualized and safer.

Fengrui Xu1, Zefei Jiang1.   

Abstract

Entities:  

Year:  2020        PMID： 32176221      PMCID： PMC7048996          DOI： 10.21037/atm.2019.12.50

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  5 in total

1.  Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).

Authors:  G Rossi; A Donisi; S Casari; A Re; R Stellini; G Cadeo; G Carosi
Journal:  Haematologica       Date:  1998-04       Impact factor: 9.941

2.  Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840.

Authors:  S M Lichtman; A Hurria; C T Cirrincione; A D Seidman; E Winer; C Hudis; H J Cohen; H B Muss
Journal:  Ann Oncol       Date:  2011-06-21       Impact factor: 32.976

3.  Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.

Authors:  Jianbin Li; Shusen Wang; Yongsheng Wang; Xiaojia Wang; Haibo Wang; Jifeng Feng; Qingyuan Zhang; Tao Sun; Quchang Ouyang; Yongmei Yin; Yinhua Liu; Cuizhi Geng; Min Yan; Zefei Jiang
Journal:  Oncologist       Date:  2017-08-10

4.  Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial.

Authors:  Fengrui Xu; Yang Zhang; Zhanhui Miao; Xiaohua Zeng; Biao Wu; Li Cai; Jinping Liu; Shusen Wang; Xichun Hu; Wenbo Zheng; Zhiyue Chen; Qing Yang; Zefei Jiang
Journal:  Ann Transl Med       Date:  2019-09

5.  Physician attitudes about cost consciousness for breast cancer treatment: differences by cancer sub-specialty.

Authors:  Ken Resnicow; Minal R Patel; M Chandler Mcleod; Steven J Katz; Reshma Jagsi
Journal:  Breast Cancer Res Treat       Date:  2018-09-26       Impact factor: 4.624
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.